{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:16:42Z","timestamp":1787915802606,"version":"build-2784847793"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Head and neck squamous cell carcinoma (HNSCC) remains difficult to treat, particularly in patients with HPV-negative disease. These patients often get diagnosed too late, their cancer doesn\u2019t respond well to treatment, and they don\u2019t live as long. Oncolytic viruses (OVs) can be used for treating cancer instead of using other cytotoxic methods since they can kill malignant cells directly and cause both local and systemic anti-cancer immune responses. In this review, we focus on current evidence of oncolytic virotherapy (OVT) in HNSCC, including that OVs selectively infect tumor cells, induce tumor cell lysis and immunogenic cell death, and modulate the tumor microenvironment. We also compare some OV platforms which were studied in HNSCC or similar solid-tumor settings: Herpes simplex virus (HSV), adenovirus, vaccinia virus, reovirus, measles virus, vesicular stomatitis virus, and Newcastle disease virus. Finally, we discuss emerging strategies to improve the efficacy and clinical translation of OVT for HNSCC, including tumor- or stimulus-responsive promoters, engineering of viral tropism and receptor specificity, modulation of both antiviral and immunosuppressive pathways, and incorporation between therapeutic payloads and advanced delivery systems. Altogether these developments support further exploration of OVs within biomarker-informed multimodal therapy for select patients of HNSCC.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1889008","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:30:16Z","timestamp":1787913016000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic viruses in head and neck cancer: therapeutic promise and translational challenges"],"prefix":"10.3389","volume":"17","author":[{"given":"Haiting","family":"Wang","sequence":"first","affiliation":[{"name":"Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, Shandong, China"]},{"name":"Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation","place":["Yantai, Shandong, China"]},{"name":"Yantai Key Laboratory of Otorhinolaryngologic Diseases","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shen","sequence":"additional","affiliation":[{"name":"Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, Shandong, China"]},{"name":"Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation","place":["Yantai, Shandong, China"]},{"name":"Yantai Key Laboratory of Otorhinolaryngologic Diseases","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, Shandong, China"]},{"name":"Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation","place":["Yantai, Shandong, China"]},{"name":"Yantai Key Laboratory of Otorhinolaryngologic Diseases","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakui","family":"Mou","sequence":"additional","affiliation":[{"name":"Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, Shandong, China"]},{"name":"Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation","place":["Yantai, Shandong, China"]},{"name":"Yantai Key Laboratory of Otorhinolaryngologic Diseases","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ren","sequence":"additional","affiliation":[{"name":"Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, Shandong, China"]},{"name":"Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation","place":["Yantai, Shandong, China"]},{"name":"Yantai Key Laboratory of Otorhinolaryngologic Diseases","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[{"name":"Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, Shandong, China"]},{"name":"Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation","place":["Yantai, Shandong, China"]},{"name":"Yantai Key Laboratory of Otorhinolaryngologic Diseases","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchen","family":"Liu","sequence":"additional","affiliation":[{"name":"Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, Shandong, China"]},{"name":"Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation","place":["Yantai, Shandong, China"]},{"name":"Yantai Key Laboratory of Otorhinolaryngologic Diseases","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyu","family":"Sun","sequence":"additional","affiliation":[{"name":"Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, Shandong, China"]},{"name":"Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation","place":["Yantai, Shandong, China"]},{"name":"Yantai Key Laboratory of Otorhinolaryngologic Diseases","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxian","family":"Li","sequence":"additional","affiliation":[{"name":"Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, Shandong, China"]},{"name":"Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation","place":["Yantai, Shandong, China"]},{"name":"Yantai Key Laboratory of Otorhinolaryngologic Diseases","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Li","sequence":"additional","affiliation":[{"name":"Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, Shandong, China"]},{"name":"Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation","place":["Yantai, Shandong, China"]},{"name":"Yantai Key Laboratory of Otorhinolaryngologic Diseases","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Qu","sequence":"additional","affiliation":[{"name":"Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, Shandong, China"]},{"name":"Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation","place":["Yantai, Shandong, China"]},{"name":"Yantai Key Laboratory of Otorhinolaryngologic Diseases","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Song","sequence":"additional","affiliation":[{"name":"Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, China"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University","place":["Yantai, Shandong, China"]},{"name":"Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation","place":["Yantai, Shandong, China"]},{"name":"Yantai Key Laboratory of Otorhinolaryngologic Diseases","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/medsci11020042","article-title":"Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma","volume":"11","author":"Barsouk","year":"2023","journal-title":"Med Sci (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.06.1291","article-title":"Clinical implications of human papillomavirus in head and neck cancers","volume":"24","author":"Fakhry","year":"2006","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2012.02.002","article-title":"Future directions and treatment strategies for head and neck squamous cell carcinomas","volume":"160","author":"Wise-Draper","year":"2012","journal-title":"Transl Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.coms.2018.06.001","article-title":"Epidemiology and demographics of the head and neck cancer population","volume":"30","author":"Cohen","year":"2018","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2982","article-title":"The molecular biology of head and neck cancer","volume":"11","author":"Leemans","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.13201\/j.issn.2096-7993.2023.09.001","article-title":"Comprehensive treatment strategies for head neck tumors","volume":"37","author":"Huang","year":"2023","journal-title":"Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312990","article-title":"The potential of oncolytic virotherapy in the treatment of head and neck cancer: A comprehensive review","volume":"25","author":"Spirito","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.212","article-title":"Fighting cancer with viruses: Oncolytic virus therapy in China","volume":"29","author":"Wei","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-12-2687","article-title":"Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans","volume":"73","author":"Breitbach","year":"2013","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-3149","article-title":"Molecular pathways: multimodal cancer-killing mechanisms employed by oncolytic vesiculoviruses","volume":"19","author":"Mahoney","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1044433","article-title":"Arming oncolytic viruses to leverage antitumor immunity","volume":"15","author":"de Gruijl","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000415","article-title":"A new oncolytic Vacciniavirus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery","volume":"8","author":"Ahmed","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/mt.2014.177","article-title":"Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV","volume":"23","author":"Mazzacurati","year":"2015","journal-title":"Mol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2010.02.008","article-title":"United virus: the oncolytic tag-team against cancer","volume":"21","author":"Le Boeuf","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.3390\/ijms24043681","article-title":"The dilemma of HSV-1 oncolytic virus delivery: The method choice and hurdles","volume":"24","author":"Tang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-2667","article-title":"Molecular pathways: mechanism of action for Talimogene Laherparepvec, a new oncolytic virus immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omto.2017.05.002","article-title":"Reolysin and histone deacetylase inhibition in the treatment of head and neck squamous cell carcinoma","volume":"5","author":"Jaime-Ramirez","year":"2017","journal-title":"Mol Ther Oncolytics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.011.10301","article-title":"Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma","volume":"30","author":"Wang","year":"2011","journal-title":"Chin J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00149","article-title":"Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials","volume":"7","author":"Eissa","year":"2017","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.3390\/biomedicines10092151","article-title":"Immunotherapy in head and neck cancer when, how, and why","volume":"10","author":"Pereira","year":"2022","journal-title":"Biomedicines"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.wjorl.2016.05.009","article-title":"The current status of oncolytic viral therapy for head and neck cancer","volume":"2","author":"Old","year":"2016","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003254","article-title":"VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects","volume":"9","author":"Bazan-Peregrino","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"102027","DOI":"10.1016\/j.omtn.2023.09.004","article-title":"Construction and application of adenoviral vectors","volume":"34","author":"Zhang","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2014.22","article-title":"Evaluation of apoptogenic adenovirus type 5 oncolytic vectors in a Syrian hamster head and neck cancer model","volume":"21","author":"Vijayalingam","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1231","article-title":"Oncolytic effect of Midkine promoter-based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891","volume":"3","author":"Uehara","year":"2020","journal-title":"Cancer Rep (Hoboken)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.oraloncology.2016.02.014","article-title":"Oncolytic adenoviruses targeted to human papilloma virus-positive head and neck squamous cell carcinomas","volume":"56","author":"LaRocca","year":"2016","journal-title":"Oral Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000353854","article-title":"Vaccinia virus outperforms a panel of other poxviruses as a potent oncolytic agent for the control of head and neck squamous cell carcinoma cell lines","volume":"57","author":"Nichols","year":"2014","journal-title":"Intervirology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009062","article-title":"Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells","volume":"12","author":"DePeaux","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-368","article-title":"Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway","volume":"12","author":"Twigger","year":"2012","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113219","article-title":"Past, present and future of oncolytic reovirus","volume":"12","author":"M\u00fcller","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002096","article-title":"Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis","volume":"9","author":"Gebremeskel","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s40463-015-0062-x","article-title":"Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma","volume":"44","author":"Cooper","year":"2015","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.01.001","article-title":"The PERK inhibitor GSK2606414 enhances reovirus infection in head and neck squamous cell carcinoma via an ATF4-dependent mechanism","volume":"16","author":"McLaughlin","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666170222125035","article-title":"Clinical trials with oncolytic measles virus: current status and future prospects","volume":"18","author":"Msaouel","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"B42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/hum.2011.128","article-title":"Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy","volume":"23","author":"Li","year":"2012","journal-title":"Hum Gene Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2011.75","article-title":"Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD\/UPRT-armed oncolytic measles virus","volume":"19","author":"Zaoui","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.035","article-title":"Oncolytic viruses as cancer therapeutics: From mechanistic insights to clinical translation","volume":"33","author":"Alwithenani","year":"2025","journal-title":"Mol Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00726-w","article-title":"SMAC-armed oncolytic virotherapy enhances the anticancer activity of PD1 blockade by modulating PANoptosis","volume":"13","author":"Chen","year":"2025","journal-title":"biomark Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2013.55","article-title":"Overcoming cancer cell resistance to VSV oncolysis with JAK1\/2 inhibitors","volume":"20","author":"Escobar-Zarate","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.898631","article-title":"Immunovirotherapy based on recombinant vesicular stomatitis virus: Where are we","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/v10020090","article-title":"Oncotargeting by vesicular stomatitis virus (VSV): Advances in cancer therapy","volume":"10","author":"Bishnoi","year":"2018","journal-title":"Viruses"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nri2314","article-title":"Interferon-inducible antiviral effectors","volume":"8","author":"Sadler","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23502","article-title":"Preclinical safety and activity of recombinant VSV-IFN-\u03b2 in an immunocompetent model of squamous cell carcinoma of the head and neck","volume":"36","author":"Kurisetty","year":"2014","journal-title":"Head Neck"},{"key":"B51","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/mt.2008.286","article-title":"Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses","volume":"17","author":"Zamarin","year":"2009","journal-title":"Mol Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.virusres.2014.02.016","article-title":"Newcastle disease virus: current status and our understanding","volume":"184","author":"Ganar","year":"2014","journal-title":"Virus Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21609","article-title":"Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer","volume":"33","author":"Li","year":"2011","journal-title":"Head Neck"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer","volume":"25","author":"Rosewell Shaw","year":"2017","journal-title":"Mol Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01100-x","article-title":"Viral infection and antiviral immunity in the oral cavity","volume":"25","author":"Hickman","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.194","article-title":"Perioperative events influence cancer recurrence risk after surgery","volume":"15","author":"Hiller","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12943-019-1058-3","article-title":"Surgical stress and cancer progression: the twisted tango","volume":"18","author":"Chen","year":"2019","journal-title":"Mol Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.10.018","article-title":"Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project","volume":"126","author":"Lassen","year":"2018","journal-title":"Radiother Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1146\/annurev-med-051914-021907","article-title":"HPV-associated head and neck cancer: unique features of epidemiology and clinical management","volume":"67","author":"Maxwell","year":"2016","journal-title":"Annu Rev Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20180047","article-title":"HPV, hypoxia and radiation response in head and neck cancer","volume":"92","author":"G\u00f6ttgens","year":"2019","journal-title":"Br J Radiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.33329","article-title":"Prognostic score predicts survival in HPV-negative head and neck squamous cell cancer patients","volume":"15","author":"Qian","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2008.76","article-title":"Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation","volume":"16","author":"McNally","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2010.05.002","article-title":"Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion","volume":"20","author":"Bourboulia","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2012.07.019","article-title":"Oncolytic vaccinia virus and radiotherapy in head and neck cancer","volume":"49","author":"Mansfield","year":"2013","journal-title":"Oral Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.230","article-title":"Development of gene therapeutics for head and neck cancer in China: from bench to bedside","volume":"29","author":"Guo","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2011.01.018","article-title":"Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines","volume":"38","author":"Sakakibara","year":"2011","journal-title":"Auris Nasus Larynx"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23309","article-title":"Telomerase-specific oncolytic adenovirus: antitumor effects on radiation-resistant head and neck squamous cell carcinoma cells","volume":"36","author":"Takahashi","year":"2014","journal-title":"Head Neck"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03237","article-title":"Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline","volume":"39","author":"Chen","year":"2021","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02846-x","article-title":"Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages","volume":"23","author":"Dong","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-0553","article-title":"Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects","volume":"20","author":"Yoo","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.11.005","article-title":"Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures","volume":"46","author":"Dias","year":"2010","journal-title":"Eur J Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.794251","article-title":"Adenovirus encoding tumor necrosis factor alpha and interleukin 2 induces a tertiary lymphoid structure signature in immune checkpoint inhibitor refractory head and neck cancer","volume":"13","author":"Clubb","year":"2022","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01721","article-title":"The evolving landscape of PD-1\/PD-L1 pathway in head and neck cancer","volume":"11","author":"Qiao","year":"2020","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-1170","article-title":"Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, phase 1b study","volume":"26","author":"Harrington","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230053","article-title":"An oncolytic virus-delivered TGF\u03b2 inhibitor overcomes the immunosuppressive tumor microenvironment","volume":"220","author":"DePeaux","year":"2023","journal-title":"J Exp Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-10-0155","article-title":"Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication","volume":"70","author":"Passer","year":"2010","journal-title":"Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2015.3","article-title":"Ultrasound as a method to enhance antitumor ability of oncolytic herpes simplex virus for head and neck cancer","volume":"22","author":"Okunaga","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29386","article-title":"Deciphering head and neck cancer microenvironment: single-cell and spatial transcriptomics reveals human papillomavirus-associated differences","volume":"96","author":"Lee","year":"2024","journal-title":"J Med Virol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s44276-024-00091-5","article-title":"Temporal evolution and inter-patient heterogeneity in primary and recurrent head and neck squamous cell carcinoma","volume":"2","author":"Bresadola","year":"2024","journal-title":"BJC Rep"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1038\/s41467-024-46912-6","article-title":"Single cell deciphering of progression trajectories of the tumor ecosystem in head and neck cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1446085","article-title":"Progression of oncolytic virus in liver cancer treatment","volume":"14","author":"Hua","year":"2024","journal-title":"Front Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","article-title":"Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients","volume":"188","author":"Zhong","year":"2025","journal-title":"Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00735-11","article-title":"A recombinant vesicular stomatitis virus bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores fusion","volume":"85","author":"Stanifer","year":"2011","journal-title":"J Virol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01379","article-title":"SMAD4 somatic mutations in head and neck carcinoma are associated with tumor progression","volume":"9","author":"Lin","year":"2019","journal-title":"Front Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07670-z","article-title":"TMEFF1 is a neuron-specific restriction factor for herpes simplex virus","volume":"632","author":"Dai","year":"2024","journal-title":"Nature"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102746","article-title":"Intratumoral therapies in head and neck squamous cell carcinoma: a systematic review and future perspectives","volume":"127","author":"Jim\u00e9nez-Labaig","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"B95","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1158\/1078-0432.Ccr-20-2400","article-title":"Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma","volume":"27","author":"Kiyokawa","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197073","article-title":"Efficient delivery and replication of oncolytic virus for successful treatment of head and neck cancer","volume":"21","author":"Hamada","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.2770","article-title":"Sustained local delivery of oncolytic short hairpin RNA adenoviruses for treatment of head and neck cancer","volume":"16","author":"Jung","year":"2014","journal-title":"J Gene Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008514","article-title":"ATM-mediated DNA double-strand break response facilitated oncolytic Newcastle disease virus replication and promoted syncytium formation in tumor cells","volume":"16","author":"Ren","year":"2020","journal-title":"PLoS Pathog"},{"key":"B99","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","article-title":"Oncolytic viruses: advanced strategies in cancer therapy","volume":"11","author":"Xiao","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146900","article-title":"Systemic delivery strategies for oncolytic viruses: advancing targeted and efficient tumor therapy","volume":"26","author":"Xia","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113822","article-title":"Formulation-optimized oncolytic viruses: Advancing systemic delivery and immune amplification","volume":"383","author":"Ma","year":"2025","journal-title":"J Control Release"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142296","article-title":"Cell carriers for oncolytic virus delivery: Prospects for systemic administration","volume":"17","author":"Sarkisova","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B103","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.ccell.2022.08.001","article-title":"Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance","volume":"40","author":"Zheng","year":"2022","journal-title":"Cancer Cell"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-26-0601","article-title":"Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy","author":"Jove","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1038\/s41467-023-38679-z","article-title":"Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy","volume":"14","author":"Ban","year":"2023","journal-title":"Nat Commun"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/v15010218","article-title":"Evaluation of human mesenchymal stromal cells as carriers for the delivery of oncolytic HAdV-5 to head and neck squamous cell carcinomas","volume":"15","author":"Nilson","year":"2023","journal-title":"Viruses"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155541","article-title":"Expression and prognosis of DSG-2, CXADR, CD46 in head and neck squamous cell carcinoma","volume":"262","author":"Seuthe","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-20-0134","article-title":"Retargeted and stealth-modified oncolytic measles viruses for systemic cancer therapy in measles immune patients","volume":"19","author":"Bah","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08717-5","article-title":"Oncolytic virus VG161 in refractory hepatocellular carcinoma","volume":"641","author":"Shen","year":"2025","journal-title":"Nature"},{"key":"B110","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.immuni.2019.07.003","article-title":"Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance","volume":"51","author":"Rivadeneira","year":"2019","journal-title":"Immunity"},{"key":"B111","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1038\/s41467-024-49718-8","article-title":"Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma","volume":"15","author":"Lorenzo-Sanz","year":"2024","journal-title":"Nat Commun"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01367-1","article-title":"Genetic immune escape landscape in primary and metastatic cancer","volume":"55","author":"Mart\u00ednez-Jim\u00e9nez","year":"2023","journal-title":"Nat Genet"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1889008\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:30:18Z","timestamp":1787913018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1889008\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":113,"alternative-id":["10.3389\/fimmu.2026.1889008"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1889008","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1889008"}}